Supaveda · Ingredient Spotlight
Tagar
Valeriana wallichii DC. — Indian Valerian
Also known as: Sugandhbala · Nidrakaraka · Tagara · Baalaka · Mushkabala
Tagar (Valeriana wallichii) is the Himalayan nervine tonic that Ayurveda has relied upon for thousands of years to calm an overactive mind, induce restful sleep, and settle the nervous system. Found growing wild between 8,000 and 10,000 feet across the Himalayan arc from Kashmir to Bhutan, its aromatic rhizome carries within it one of the most well-characterised mechanisms of any sleep herb in modern pharmacology.
Classical Ayurvedic texts name Tagar Nidrajanaka — "that which induces sleep" — and Vedanasthapaka — "that which settles pain." It is described in the Charaka Samhita, Sushruta Samhita, and Ashtanga Hridayam as a premier herb for Anidra (insomnia), anxiety, and neurological disorders arising from aggravated Vata dosha. 1 Modern pharmacology has confirmed that its primary mechanism — modulation of GABA-A receptors in the central nervous system — is the same pathway targeted by benzodiazepines, making Tagar one of the best-understood natural sedative herbs in existence.
Tagar vs European Valerian — An Important Distinction
Valeriana wallichii (Indian Tagar) and Valeriana officinalis (European Valerian) are closely related members of the same genus but are pharmacologically distinct. Both share GABA-modulating properties, but their primary active constituents differ: V. officinalis is characterised by valerenic acid and acetoxyvalerenic acid; V. wallichii is richer in valepotriates and iridoids, and contains lower concentrations of valerenic acid. 2
This distinction matters clinically: valepotriates have been independently confirmed to reduce wake time after sleep onset (WASO) and improve sleep quality in an RCT of insomnia patients. 3 Tagar's traditional Ayurvedic profile — grounding, Vata-pacifying, deeply sedative — reflects this distinct phytochemical character. The majority of the world's clinical sleep research uses V. officinalis; where studies specifically use V. wallichii, this is clearly noted.
At a Glance — Key Evidence-Backed Benefits
Traditional Ayurvedic Uses
Tagar is consistently described across the three major classical Ayurvedic compilations — Charaka Samhita, Sushruta Samhita, and Ashtanga Hridayam — as a primary nervine herb. In the Bhavaprakasha Nighantu (c. 1550 CE), its properties are captured in a well-known verse: Tagaradvayamushnamsyatsvadusunigdhalaghusmritam / Vishapasmaragulashularogadoshatrayapaham — "Tagar is heating, sweet, unctuous, and light; it destroys poison, epilepsy, abdominal pain, and diseases of the three doshas." 1
Its two Sanskrit synonyms encode its two primary therapeutic identities: Nidrakaraka (sleep-inducing) and Sugandhbala (the fragrant one that gives strength) — reflecting both its sedative function and its role as a restorative nervine tonic for the exhausted nervous system. The herb is classified as Manas Vikar Shamak (calmer of mental disorders) and Mastishak Shamak (calmer of the brain) in classical categorisation. 4
Ayurvedic Properties (Guna)
*The combination of Laghu (light) and Snigdha (unctuous) is noted in classical texts as a rare and exceptional combination in Ayurvedic pharmacology — Tagar is specifically described as Guna Viruddha (containing opposing qualities), which classically indicates a herb with unusually broad and powerful therapeutic action.
Conditions Traditionally Treated
- Anidra (insomnia) — Tagar's foremost and most established classical indication
- Anxiety, mental restlessness, and stress-related disorders (Manasa Roga)
- Epilepsy and convulsions (Apasmara) — used in medicated oils applied to the head and inhaled as smoke
- Headache, migraine, and neuralgia — classified as Vedanasthapaka (pain-reliever)
- Abdominal colic, intestinal spasm, and nervous stomach (Shula)
- Hypertension — relaxes vascular smooth muscle and reduces heart rate preclinically
- Poisoning and fever — listed in Charaka Samhita as a remedy for snake venom
- Tremors and motor irregularities related to Vata excess
How It Was Traditionally Administered
The dried rhizome powder (Churna) of Tagar is the primary form used in Ayurveda, typically administered with warm milk or warm water before bedtime for insomnia, or with ghee for neurological conditions. The classical dose for Anidra in the landmark Ayurvedic clinical study was 4g of Churna with milk, three times daily. 5 In Nasya (nasal therapy), medicated oils containing Tagar were instilled into the nostrils to treat headache, epilepsy, and psychiatric disorders — a route that bypasses first-pass metabolism and allows direct access to the olfactory-brain pathway. In classical compound formulas, Tagar is frequently combined with Brahmi, Jatamansi (Nardostachys jatamansi), and Ashwagandha for comprehensive nervous system support.
Key Active Compounds
Valeriana wallichii's pharmacological activity arises from a complex mixture of iridoids, valepotriates, sesquiterpene acids, alkaloids, and flavonoids — with valepotriates and iridoids present at notably higher concentrations than in V. officinalis. 2 This phytochemical character gives Indian Tagar a distinctly different but equally potent profile to its European relative.
Primary Bioactive Constituents of V. wallichii
The GABA Mechanism — How Tagar Calms the Brain
Tagar's sedative and anxiolytic effects are now understood at a molecular level, with multiple peer-reviewed studies identifying the precise mechanism by which its compounds interact with the brain's primary inhibitory neurotransmitter system. This mechanistic clarity is rare for herbal medicines and places Tagar among the most scientifically well-characterised natural sleep herbs. 67
Tagar's Four-Level CNS Calming Mechanism
The critical distinction from pharmaceutical benzodiazepines is in the binding site: benzodiazepines bind to the γ subunit of GABA-A receptors; valerenic acid binds to the β subunit. Both enhance GABA's inhibitory effect on the neuron, but the different binding site means Valeriana compounds do not carry the same tolerance, dependency, or withdrawal risks associated with benzodiazepines. 7 This pharmacological nuance precisely validates Ayurveda's use of Tagar as a safe, long-term nervine tonic — rather than a short-term sedative.
How Indian Tagar Differs from European Valerian
Understanding what makes V. wallichii distinct from V. officinalis is important for accurately interpreting research. Most large-scale clinical trials use V. officinalis; V. wallichii has a smaller but growing direct evidence base of its own.
What the Research Says
While the largest clinical datasets use V. officinalis, V. wallichii has a growing body of direct evidence — including a PMC-indexed comparative Ayurvedic clinical study, a recent 200-person occupational stress quasi-RCT, and specific inclusion in the Shinjyo et al. (2020) systematic review in Journal of Alternative and Complementary Medicine (one of the most comprehensive valerian systematic reviews to date). 3
The most significant direct clinical evidence on V. wallichii for sleep is the comparative clinical study published in AYU (indexed on PMC), in which 30 patients with primary insomnia were randomised to receive either Tagar Churna (4g with milk, three times daily for 30 days) or Jatamansi Churna under the same protocol. 5 Tagar produced statistically significant improvements across all four primary outcomes: initiation of sleep (76.00%; p < 0.001), duration of sleep (55.17%; p < 0.001), disturbed sleep (69.58%; p < 0.001), and disturbances in routine work due to poor sleep (73.95%; p < 0.001). Tagar outperformed Jatamansi on all four measures. Both drugs were well tolerated with no adverse events. This is the most direct RCT evidence for Tagar's classical use in Anidra.
A randomised clinical trial specifically using valepotriates from V. wallichii (300 mg per day for 15 days) demonstrated significant reduction in Wake Time After Sleep Onset (WASO) and improved sleep quality in insomnia patients. 3 This is directly relevant to Tagar specifically — as V. wallichii is particularly rich in valepotriates relative to V. officinalis, this RCT aligns the primary active class of Indian Tagar with a demonstrated sleep benefit in human subjects. The study was included in the Shinjyo et al. (2020) systematic review of all valerian species for sleep, which analysed a total of 60 studies and concluded that valerian species may improve sleep quality without producing adverse effects. 3
A 2024 quasi-experimental study conducted with 200 nursing staff randomised into two groups (Tagara + CBT, n=100; CBT alone, n=100) evaluated Tagar's effect on occupational stress, anxiety, and sleepiness in a real-world healthcare setting. The Tagara + CBT group showed significantly greater reductions in occupational stress scores, anxiety (measured by validated scales), and daytime sleepiness than the CBT-only group. 8 While a quasi-experimental design has limitations compared to a double-blind RCT, the study is significant for demonstrating clinically meaningful anxiolytic and sleep-supporting effects of V. wallichii in a human population under real occupational conditions — and its sample size of 200 is among the largest for any direct Tagar human study.
A 2024 double-blind, placebo-controlled, parallel RCT published in Advances in Therapy (Springer Nature) administered standardised V. officinalis extract (VE, 2% total valerenic acid) to 80 adults with sleep complaints for 8 weeks. The VE group showed statistically significant improvements in overall sleep quality (PSQI), sleep latency, actual sleep time, and sleep efficiency by wrist actigraphy, alongside decreased anxiety (Beck Anxiety Inventory) and daytime sleepiness (Epworth Sleepiness Scale). No adverse effects were reported. 9 While this uses V. officinalis, the GABA-A mechanism is shared across Valeriana species, and the magnitude and breadth of improvement in this well-designed trial is directly informative for understanding the therapeutic class to which Tagar belongs.
A study by Hattesohl et al. (2008) demonstrated that V. wallichii extract exhibits anxiolytic, sedative, antidepressant, and myorelaxant properties in animal models, establishing that these effects are present specifically in the Indian species. 10 Antispasmodic activity of Tagar has been demonstrated in isolated intestinal smooth muscle preparations, consistent with its Ayurvedic use for Shula (abdominal colic) and nervous stomach. A separate preclinical study published in Pharmacognosy Research confirmed that V. wallichii reduces oxidative markers in brain tissue, providing evidence for its neuroprotective classification. 4 The combination of anxiolytic, antispasmodic, and neuroprotective activity mirrors the comprehensive nervous system support that classical Ayurvedic texts describe — calming both the mind and the peripheral nervous system simultaneously.
A review by Lanje et al. (2020) summarised evidence showing Tagar may have antiarrhythmic and coronary dilating effects in animal models, lowering blood pressure and reducing heart rate. 10 The mechanism is consistent with Tagar's smooth muscle relaxant activity — the same GABA-ergic and antispasmodic mechanisms that calm gut spasm also relax vascular smooth muscle, reducing peripheral resistance and thereby lowering blood pressure. Notably, Tagar was historically included in a German heart tonic preparation specifically for its cardiac calming properties. This cardiovascular dimension of Tagar's action — though primarily preclinical — is entirely consistent with Ayurveda's classical description of the herb as a heart-stabilising, Vata-pacifying tonic.
The Clinical Evidence at a Glance
The Toolika et al. (2015) clinical study — published in AYU and indexed on PMC — is the primary direct clinical evidence for Tagar (V. wallichii specifically) in primary insomnia. 5
Tagar in Primary Insomnia — Clinical Study Results (Toolika et al., 2015, AYU / PMC)
In the broader context of the Valeriana genus, the Shinjyo et al. (2020) systematic review of 60 studies (including V. wallichii) concluded that valerian species may improve sleep quality without producing side effects, with a statistically significant overall benefit across pooled dichotomous outcomes (relative risk of improved sleep = 1.8, 95% CI 1.2–2.9) in the Fernández-San-Martín et al. meta-analysis. 3
Traditional Use & Modern Dosage
Tagar is most effective when taken in the evening or before sleep for insomnia, and during the day for anxiety and nervous conditions. The classical evidence base uses the powder with warm milk — a delivery method that remains optimal given milk's protein content may enhance absorption of some fat-soluble terpenoids.
| Form | Traditional Preparation | Typical Dose (Adult) |
|---|---|---|
| Powder (Churna) | Dried rhizome powder with warm milk or warm water — the form used in the primary clinical study | 1–4 g/day; 1–2 g before bed for sleep; up to 4 g (divided) for anxiety |
| Capsules / Tablets | Standardised extract or whole rhizome powder in modern encapsulation | 250–500 mg, 1–2× daily; follow product guidance |
| Decoction (Kwath) | Rhizome simmered in water or milk and strained; traditional preparation for insomnia | 20–40 ml before bed; 1–2 tsp dried root per cup |
| Medicated Oil (Taila) | Tagar-infused sesame oil applied to scalp, temples, and soles of feet; classical Shiroabhyanga for insomnia and headache | Apply 1–2× daily topically; warm oil massage before bed |
| In Herbal Blend (SupaSleep) | Standardised Tagar combined with Brahmi and Manuka in SupaSleep formula | As directed on product — typically 1–2 capsules 30–60 minutes before bed |
Tagar is traditionally taken on a cycle of 4–8 weeks, with a rest period. For chronic insomnia, longer courses under practitioner guidance are established in Ayurvedic practice. The herb is best taken 30–60 minutes before the intended sleep time, allowing the valepotriates and sesquiterpenes to reach the CNS before sleep onset.
Supaveda Products with Tagar
Tagar features in SupaSleep — our dedicated sleep support formula — where it provides the core nervous system calming and sleep-initiating action of the blend:
An organic blend of three Ayurvedic sleep and nervous system herbs — Tagar (Valeriana wallichii), Brahmi (Bacopa monnieri), and Manuka (Vitis vinifera). Tagar is the centrepiece: its valepotriates modulate GABA-A receptors to calm neuronal excitability and initiate sleep. Brahmi reduces cortisol and settles anxious mental chatter. Manuka contributes naturally occurring melatonin to signal the brain's circadian sleep onset. Together, they address all three Ayurvedic causes of poor sleep — nervous Vata, hot Pitta, and an over-stimulated mind — providing a comprehensive, non-dependency-forming alternative to pharmaceutical sedatives.
Our organic, vegan Chyawanprash — 16 Ayurvedic herbs including Tagar in a base of jaggery and coconut oil. In the classical Chyawanprash formula, Tagar contributes its Vata-pacifying and nervous system-calming properties to the overall rejuvenative blend — helping maintain the emotional stability and mental groundedness that supports long-term vitality.
Safety & Precautions
Tagar has a well-established safety profile when used within recommended doses. The clinical study by Toolika et al. (2015) and the broader valerian literature report no significant adverse events at standard therapeutic doses. 5 The following precautions apply:
Please note
- Sedative medications & CNS depressants: Tagar potentiates the effect of other CNS depressants — including benzodiazepines, other sedative herbs, and alcohol. Do not combine with prescription sedatives or anxiolytics without medical guidance, as excessive sedation can result. 1
- Antihypertensive drugs: Tagar may enhance the blood pressure-lowering effects of antihypertensive medication — those on such drugs should monitor blood pressure and consult a healthcare provider before use. 10
- Daytime use: Due to its sedative properties, higher doses of Tagar should not be taken before driving or operating machinery. Standard doses used specifically for sleep are generally safe but avoid daytime high-dose use.
- Pregnancy & breastfeeding: Valepotriates have shown cytotoxic effects in cell studies — Tagar is traditionally contraindicated in pregnancy. Avoid internal therapeutic use during pregnancy and breastfeeding.
- Children: Use only under the supervision of a qualified Ayurvedic practitioner at age-appropriate doses.
- Long-term use: Tagar is generally safe for 4–8 week therapeutic cycles. For longer use, periodic breaks and practitioner monitoring are advised. No dependency has been reported at standard doses, consistent with the non-benzodiazepine binding site.
Key Takeaways
Evidence-backed bullet points:
Sanskrit name Nidrajanaka means "that which induces sleep" — named with precision by Ayurvedic physicians for its most observed and reliable clinical effect
Grows wild in the Himalayas at 8,000–10,000 feet — one of Ayurveda's premier high-altitude nervine herbs, used for over 3,000 years
Modulates GABA-A receptors at the β subunit — the same pathway as benzodiazepines, but at a different binding site and without dependency risk
Ayurvedic clinical study: 76% improvement in sleep initiation and 55% in sleep duration — all outcomes statistically significant (p < 0.001)
Head-to-head comparison: Tagar outperformed Jatamansi (another classical sleep herb) on all four sleep outcome measures
200-person occupational study: Tagar + CBT significantly outperformed CBT alone for stress, anxiety & sleepiness in nursing staff
Rich in valepotriates — iridoid compounds that distinguish Indian Tagar from European Valerian and were independently shown to reduce wake time in an RCT
Also raises brain GABA levels by inhibiting GABA-transaminase — the enzyme that breaks down this key calming neurotransmitter
Described in classical texts as Guna Viruddha — containing the rare combination of opposing qualities that signals exceptional therapeutic breadth
Non-dependency forming at standard doses — safe for 4–8 week cycles; avoid combining with prescription sedatives or alcohol
References
- Yadav, V.S. and Maurya, B.N. (2022) 'Ayurvedic drug review of Tagar (Valeriana wallichii)', Ayurvedic ISSNj, 2277-4270, December 2021. Available at: https://www.researchgate.net/publication/362067158
- Shinjyo, N., Waddell, G. and Green, J. (2020) 'Valerian root in treating sleep problems and associated disorders — a systematic review and meta-analysis', Journal of Evidence-Based Integrative Medicine, 25, pp.1–31. doi: 10.1177/2515690X20967323. PMC7585905. [Notes: V. wallichii contains higher valepotriates/iridoids; valerenic acid specific to V. officinalis].
- Shinjyo, N., Waddell, G. and Green, J. (2020) — ibid. Includes: concoction of valepotriates from V. wallichii 300 mg/day for 15 days reduced WASO and improved sleep quality in insomnia patients (RCT, Jadad scale 3); overall meta-analysis: relative risk of improved sleep = 1.8 (95% CI 1.2–2.9), 60 studies analysed.
- Tyagi, T., Sharma, S. and Sharma, R. (2022) 'Pharmacological actions of Valeriana wallichii (Tagara)', International Journal of Ayurveda and Pharma Research, 10(Suppl 1), pp.1–7. Available at: https://ijapr.in/index.php/ijapr/article/download/2468/1727/
- Toolika, E., Bhat, N.P. and Shetty, S.K. (2015) 'A comparative clinical study on the effect of Tagara (Valeriana wallichii DC.) and Jatamansi (Nardostachys jatamansi DC.) in the management of Anidra (primary insomnia)', AYU, 36(1), pp.46–49. doi: 10.4103/0974-8520.169008. PMID: 26730138. PMC4687238.
- Khom, S., Baburin, I., Timin, E., Hohaus, A., Trauner, G., Kopp, B. and Hering, S. (2007) 'Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity', Neuropharmacology, 53(1), pp.178–187. doi: 10.1016/j.neuropharm.2007.04.018. PMID: 17585957.
- Trauner, G., Khom, S., Baburin, I., Benedek, B., Hering, S. and Kopp, B. (2008) 'Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid', Planta Medica, 74(1), pp.19–24. doi: 10.1055/s-2007-993761. PMID: 18095218.
- ResearchGate (2024) 'Pharmacological actions of Valeriana wallichii (Tagara): a fundamental analysis supporting traditional benefits' [including the 200-nursing-staff quasi-experimental study, Tagara + CBT vs CBT alone, occupational stress outcomes]. Available at: https://www.researchgate.net/publication/363803964
- Shekhar, H.C., Joshua, L. and Thomas, J.V. (2024) 'Standardized extract of Valeriana officinalis improves overall sleep quality in human subjects with sleep complaints: a randomized, double-blind, placebo-controlled, clinical study', Advances in Therapy, 41(1), pp.246–261. doi: 10.1007/s12325-023-02708-6. PMID: 37899385. [V. officinalis; shared GABA-A mechanism applies to V. wallichii].
- Lanje, A. et al. (2020) review of antiarrhythmic and cardioprotective actions of Valeriana wallichii, cited in: PharmEasy (2026) 'Tagar: uses, benefits, side effects and more'. Available at: https://pharmeasy.in/blog/ayurveda-uses-benefits-side-effects-of-tagar/
- Singh, V., Singh, D.C., Tiwari, R.C. and Vashishtha, K. (2023) 'A conceptual review on Tagar (Valeriana wallichii DC) and its medicinal properties', World Journal of Pharmaceutical Research, 12(2), pp.349–358. doi: 10.20959/wjpr20232-27051.